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TAM family receptors in conjunction with
MAPK signalling are involved in acquired
resistance to PI3Kα inhibition in head and
neck squamous cell carcinoma
Kara M. Ruicci1,2, Jalna Meens3, Paul Plantinga2, William Stecho2, Nicole Pinto1, John Yoo1,4, Kevin Fung1,4,
Danielle MacNeil1,4, Joe S. Mymryk1,4,5, John W. Barrett1, Christopher J. Howlett2, Paul C. Boutros6,7,8†,
Laurie Ailles3,9† and Anthony C. Nichols1,2,4*†
Abstract
Background: Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) pathway is common in many
malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite pre-clinical and clinical studies,
outcomes from targeting the PI3K pathway have been underwhelming and the development of drug resistance poses
a significant barrier to patient treatment. In the present study, we examined mechanisms of acquired resistance to the
PI3Kα inhibitor alpelisib (formerly BYL719) in HNSCC cell lines and patient-derived xenografts (PDXs).
Methods: Five unique PDX mouse models and three HNSCC cell lines were used. All cell lines and xenografts
underwent genomic characterization prior to study. Serial drug treatment was conducted in vitro and in vivo to
develop multiple, clinically-significant models of resistance to alpelisib. We then used reverse phase protein arrays
(RPPAs) to profile the expression of proteins in parental and drug-resistant models. Top hits were validated by
immunoblotting and immunohistochemistry. Flow cytometric analysis and RNA interference studies were then used to
interrogate the molecular mechanisms underlying acquired drug resistance.
Results: Prolonged treatment with alpelisib led to upregulation of TAM family receptor tyrosine kinases TYRO3 and
AXL. Importantly, a significant shift in expression of both TYRO3 and AXL to the cell surface was detected in drug-
resistant cells. Targeted knockdown of TYRO3 and AXL effectively re-sensitized resistant cells to PI3Kα inhibition. In vivo,
resistance to alpelisib emerged following 20–35 days of treatment in all five PDX models. Elevated TYRO3 expression
was detected in drug-resistant PDX tissues. Downstream of TYRO3 and AXL, we identified activation of intracellular
MAPK signalling. Inhibition of MAPK signalling also re-sensitized drug-resistant cells to alpelisib.
(Continued on next page)
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Conclusions: We have identified TYRO3 and AXL receptors to be key mediators of resistance to alpelisib, both in vitro
and in vivo. Our findings suggest that pan-TAM inhibition is a promising avenue for combinatorial or second-line
therapy alongside PI3Kα inhibition. These findings advance our understanding of the role TAM receptors play in
modulating the response of HNSCC to PI3Kα inhibition and suggest a means to prevent, or at least delay, resistance to
PI3Kα inhibition in order to improve outcomes for HNSCC patients.
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Background
Head and neck squamous cell carcinoma (HNSCC),
which arises in the mucosa of the oral cavity, pharynx
and larynx, is the 6th most common cancer worldwide
[1]. Despite advances in available treatments (surgery,
radiation, chemotherapy), survival rates at 5 years remain
poor. Further, even patients cured by conventional treat-
ment are frequently left with impairments in their abil-
ities to speak, swallow and breathe, as well as facial
disfigurements [2]. The development and clinical imple-
mentation of targeted therapeutics is needed to improve
the survival outcomes and relieve the toxic burden asso-
ciated with current HNSCC treatments.
The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR
pathway is a major growth signalling pathway that regu-
lates a variety of cellular processes, including protein
and lipid synthesis, proliferation and cell survival [3].
The PI3K pathway is the most frequently dysregulated
pathway in HNSCC, across both HPV-positive and
HPV-negative HNSCC tumors [4–6]. Dysregulation of
PI3K signalling—stemming from activating mutations or
amplifications of PIK3CA—leads to constitutive activa-
tion of the pathway, which can promote tumor develop-
ment and progression [5–7]. Given the prevalence of
PI3K pathway alterations in HNSCC and the role this
network plays in tumorigenesis, inhibiting this pathway
is a logical therapeutic approach [7].
Various inhibitors that target one or more of the PI3K
isoforms have entered clinical trials [7]. In fact, the α-
isoform specific PI3K inhibitor alpelisib (Piqray®, Novartis)
was recently approved by the US Food and Drug Adminis-
tration (FDA) for treatment of PIK3CA-mutated, ad-
vanced or metastatic breast cancer. To date however,
PI3K inhibitors as single agents have generally displayed
limited efficacy. These drugs have typically led to cytosta-
sis, rarely inducing tumor cell death or shrinkage [7, 8].
Moreover, in patients who initially respond to targeted
PI3K inhibition, acquired resistance over time has been
cited [9].
Acquired resistance to PI3K inhibition is an area of ac-
tive research [9–14]. In ovarian cancer, elevated expres-
sion of receptor tyrosine kinases (RTKs), including
HER2 and EGFR, as well as increased activation of Src,
c-Jun and STAT3 have been implicated in mediating
resistance to PI3K inhibition by NVP-BEZ235 [11]. In
breast cancer, genetic alterations in PTEN resulting in
loss of expression have been identified in a patient who
initially achieved a clinical response to PI3K inhibition
before progressing rapidly [9]. Only a limited number of
studies to date have examined acquired resistance to
PI3K inhibition in HNSCC. Of these, resistance to the
pan-PI3K inhibitor BKM120 has been shown to involve
positive feedback activation of IL-6/ERK signalling, while
resistance to the α-isoform specific PI3K inhibitor alpeli-
sib has been associated with growth signalling through
the PLCγ-PKC network, downstream of the RTK AXL
[12, 15]. It is evident that a number of distinct mecha-
nisms and mediators of resistance to PI3K inhibition
exist and may be context-specific according to the drug
used and/or cancer type.
As mentioned, alpelisib (formerly BYL719) is an α-
isoform specific PI3K inhibitor. It has been shown to ex-
hibit “on-target” PI3K inhibition and anti-cancer efficacy,
collectively leading to its recent FDA approval for breast
cancer treatment [7, 8, 16]. Alpelisib targets the p110α
catalytic subunit of the Class IA PI3K enzyme encoded
by PIK3CA [17]. Due to the prevalence of genomic aber-
rations in PIK3CA observed in HNSCC, including gain
of function mutations and amplifications, alpelisib is a
particularly relevant drug. Further, by targeting only the
α-isoform, alpelisib has shown to have better tolerability
than other, broader-acting PI3K inhibitors, with gener-
ally manageable side effects (e.g. hyperglycemia) [8]. To
date, there have been few investigations of how resist-
ance to PI3K inhibition by alpelisib is acquired in the
context of HNSCC [12]. Further, most studies have been
limited to in vitro investigations and have not made use
of patient-derived xenograft (PDX) models to explore re-
sistance and/or validate their findings [12, 18].
To capitalize on the promise of PI3K inhibitors in
HNSCC, it is essential to understand resistance mecha-
nisms that may be acquired over time; this will enable
the design of drug combinations that will be both toler-
able and durable [19]. In the present study, we explored
acquired resistance to alpelisib using both HNSCC cell
lines and HNSCC PDXs. We observed elevated expres-
sion of the AXL RTK, in line with other studies, as well
as elevation of its family member TYRO3 in alpelisib-
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resistant HNSCC models [12]. Further, we interrogated
MAPK pathway activation downstream of AXL and
TYRO3 as a critical network for circumventing PI3K in-
hibition. Collectively our findings emphasize TYRO3
and AXL as key mediators of acquired resistance to
PI3K inhibition in HNSCC, through the MAPK pathway.
Pan-TAM inhibition may be a promising second-line
therapy for HNSCC patients receiving PI3K-targeted
agents.
Materials & methods
Cell lines and chemical compounds
Cell lines were obtained from the sources listed (Add-
itional Table 1). We previously used short tandem repeat
profiling (The Center for Applied Genetics; Toronto) to
confirm cell line identities [20]. 93-VU-147T cells were
cultured in DMEM/F12, with 10% fetal bovine serum
(FBS; GIBCO), penicillin (100 IU/mL; Invitrogen) and
streptomycin (100 μg/mL; Invitrogen). Cal33 cells were
cultured in DMEM, with 10% heat-inactivated FBS, 1x
non-essential amino acids (Wisent), penicillin (100 IU/
mL) and streptomycin (100 μg/mL). Resistant cell lines
were obtained after chronic exposure to increasing con-
centrations of alpelisib for 3–4 months [22]. All cells
were maintained in a 37 °C humidified atmosphere at 5%
CO2. The inhibitors alpelisib and BI-D1870 were pur-
chased from Selleckchem. Compounds were dissolved in
DMSO for in vitro experiments.
Establishment of patient derived xenografts
Mice were handled in accordance with the AUP 1542
approved by the University Health Network Animal Care
Committee and in accordance with the CCAC regula-
tions. Xenografts were established and handled as
described previously [21]. Details are provided as
Supplemental Methods & Materials.
Once tumor volumes reached 80-120mm3 mice were
randomized to either daily (5x/week) alpelisib (Novartis;
50 mg/kg) by oral gavage or a vehicle control (corn oil)
[12, 21]. Individual tumor volumes were calculated using
the formula: [length x (width)2] × 0.52. Where possible,
STR profiling was used to confirm matching identities of
primary tumors, xenograft tumors, patient blood and
PDX-derived cell lines where available (Additional Table
2). Tumors were classified as HPV-positive using immu-
nohistochemistry (IHC) for p16.
Dose response curves
Cells were seeded in 96-well plates at 2400 cells/well
and cultured overnight. Drugs were then added over 10-
point ranges (0-40 μM). Viability was determined 72 h
later using the PrestoBlue® Reagent (Thermo Fisher Sci-
entific) on a Synergy™ H4 Hybrid Reader (BioTek) with
560 nm excitation and 590 nm emission wavelengths.
For each dose, viability values were normalized to no-
drug controls and average viability for each dose was cal-
culated. To determine the half-maximal inhibitory con-
centration (IC50) values, normalized relative fluorescence
values of drug-treated replicates were calculated as a
percentage of the mean RFU of the control replicates
and then drug doses were transformed to a logarithmic
scale. IC50 values were subsequently calculated by non-
linear regression. Values are plotted as mean + standard
deviation (SD) using Prism® 7 GraphPad Software.
Clonogenic survival assay
Parental and resistant cell lines were counted and seeded
at 500 cells per well into 24-well dishes. Cells were
allowed to adhere for 48 h and then were treated with
media containing 5 μM alpelisib. For the next 7–14 days,
cells were monitored and media replaced every 3 days
until visible colonies were formed. Colonies were rinsed
with 1x PBS, fixed with cold 100% methanol (MeOH)
and stained with 0.5% crystal violet in 25% MeOH/1x
PBS. The colonies were then gently washed with water
and air-dried. Visible colonies were counted.
Reverse phase protein arrays
Cells were prepared for reverse phase protein arrays
(RPPAs) as follows: 10 cm plates were washed twice with
cold 1x PBS. Cold lysis buffer (containing: 1% Triton X-
100, 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM Na pyro-
phosphate, 1 mM Na3VO4, 10% glycerol and 1% freshly-
added protease and phosphatase inhibitors) was added
to the plates which were then incubated 20mins on ice
with occasional shaking. Lysed cells were centrifuged at
14000 rpm for 10mins at 4 °C. Protein concentration de-
termined by Bradford Assay. Lysates were combined
with sample buffer (40% glycerol, 8% SDS, 0.25M Tris-
HCl pH 6.8 and 1/10 volume β-mercaptoethanol –added
just before use) at 3 parts lysate:1 part sample buffer.
Samples were boiled for 5 mins and stored at − 80 °C.
Samples were submitted to MD Anderson’s Functional
Proteomics RPPA Core Facility. Briefly, lysates were seri-
ally diluted and arrayed onto nitrocellulose-coated glass
slides. Samples were probed with 307 antibodies and vi-
sualized by DAB colorimetric reaction. Slides were then
scanned and spot densities quantified by Array-Pro
Analyzer. All data points were normalized for protein
loading and transformed to a linear value. Resistant rep-
licates were then normalized to the mean of their re-
spective parental replicates. Values were then log2-
transformed and we restricted our analysis to the top
50% of differentially-expressed proteins for each cell line.
Unsupervised hierarchical clustering was performed
using the average agglomeration method and Euclidean
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distance measurements. Clustering was performed in R
using the ComplexHeatmap package (version 2.1.1).
Immunoblotting and densitometric analysis
Cell lysates were prepared for immunoblotting as de-
scribed previously [23]. A list of primary antibodies used
is provided in Additional Table 3. Membranes were visu-
alized following exposure to enhanced chemilumines-
cence reagent (Luminata™ Crescendo or Luminata™
Forte, Western HRP Substrate; Millipore) on a Bio-Rad
ChemiDoc™MP Imaging System.
ImageJ was used to select and determine the
background-subtracted density of the bands in all immu-
noblots. Values were then normalized to their corre-
sponding α-tubulin band. All values are presented below
the associated band.
Tissue microarray (TMA) and immunohistochemistry
TMAs were constructed for two of the xenograft
models. In brief, the FFPE block for each tumor was sec-
tioned and stained with hematoxylin & eosin (H & E) to
confirm the presence of human tumor. Guided by these
sections, a Manual Tissue Arrayer (MTA-1; Beecher In-
struments Inc.) was used to punch out 3–4 cylindrical
cores of 0.6 mm diameter from each sample. Cores were
arrayed into recipient paraffin blocks. Eleven control tis-
sues (tonsil, stomach, prostate, pancreas, lung, kidney,
skin, thyroid, spleen, adipose, liver) were also included
on each block. Cores were sealed into recipient blocks
by heating at 40 °C for ~40mins. Blocks were sectioned
into 1.5 μM sections and affixed to glass slides. Every
ninth slide was stained with H & E to provide a refer-
ence. Additional details are available in the MTA-1 In-
struction Manual (www.beecherinstruments.com). IHC
staining was completed in collaboration with the Depart-
ment of Pathology & Laboratory Medicine and the Mo-
lecular Pathology Core Facility (Western University).
Tissues were examined using an Aperio ScanScope® slide
scanner and staining quantification was performed using
the Fiji plugin for ImageJ.
Flow cytometry for cell surface expression of RTKs
Parental and resistant cells were collected by trypsiniza-
tion, washed in 1x PBS and counted. Single-cell suspen-
sions were incubated in a 5% BSA solution containing
anti-AXL or TYRO3, PE-conjugated antibodies at 1:50
(R & D Biosystems) for 40mins in the dark at room
temperature. Cells were passed through a cell strainer to
collect single cells and were protected from light until
they were quantified using a Beckman-Coulter Cytomics
FC500 flow cytometer with at least 10,000 events
counted per test. Histograms were used to compare in-
tensity of staining between unstained, parental and re-
sistant cell line samples. Median fluorescence intensity
was calculated for each sample and t-tests were used to
quantify differences.
RNA interference
Knockdown of AXL and TYRO3 was performed using spe-
cific pooled siRNAs purchased from Dharmacon (Cat No’s.
L-003104-00-0005 and L-003183-00-0005, respectively), as
described previously [23]. Scrambled control siRNA (siCT)
(Thermo Fisher Scientific; Cat No. 4390843) was also used.
Knockdowns were confirmed by immunoblotting.
For drug testing, cells were seeded into 96-well dishes at
2400cells/well. Alpelisib was added the next day at 5 μM
and cells were incubated for 72 h. Cell viability was then de-
termined indirectly using the PrestoBlue® Reagent (Thermo
Fisher Scientific) on a Synergy™ H4 Hybrid Reader (BioTek)
with 560 nm excitation and 590 nm emission wavelengths.
For each condition, alpelisib-treated cells were compared
with normalized untreated cells to determine the relative
effect of RNAi-mediated knockdown.
Generation of PDX-derived cell line
Using cells dissociated from first-passage xenograft tu-
mors, we attempted to establish cell lines from the pa-
tient tumors that were used to generate the PDX models
(Additional Fig. 1a). Specifically, the generation of cell
lines was attempted from tumor tissues that were never
treated with alpelisib nor the vehicle agent. A cell line
(called PDX-C Cell Line) was successfully established
from one model, PDX-C (Additional Fig. 1b). STR pro-
filing, immunoblotting and flow cytometry for cell sur-
face expression of EpCAM (CD326) were all completed
as described previously, validating the line as a human
epithelial line from the same patient as the PDX-C
tumor (Additional Fig. 1c, Additional Table 2).
(See figure on previous page.)
Fig. 1 Alpelisib inhibits growth and PI3K signalling in HNSCC cells. a Immunoblot of PI3K and MAPK pathway members Akt, ERK1/2 and P90RSK following
treatment with 5 μM alpelisib for 36 h. Densitometric quantification of each protein relative to α-tubulin is shown below each band. b Flow cytometric
analysis of Cal33 and 93-VU-147T cells treated with alpelisib (5 μM) for 24 h (3 replicates per line) before BrdU incorporation and labeling with propidium
iodide. Approximately 10,000 events were counted per test (5000 events are shown in each figure). Proportion of cells in each cell cycle phase is shown, +
standard deviation. * represents p< 0.05, ** represents p< 0.01, *** represents p< 0.001, ns = not significant, unpaired Student’s t-test. c Immunoblot for
PARP cleavage in Cal33 cells treated with alpelisib (5 μM) for 24 h, or staurosporine (2 μM) for 3 h, as a positive control. Densitometric quantification of each
protein relative to α-tubulin is shown below each band
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Fig. 2 Genomically-distinct HNSCC cell lines become resistant to PI3K inhibition over time. a Genomic features and IC50 values for Cal33 and 93-
VU-147T cell lines. b Phase contrast microscopy images of parental and resistant HNSCC cell lines, with and without 5 μM alpelisib treatment for
24 h. c Dose response curves comparing sensitivity of parental and resistant cell lines over 10 doses of alpelisib. d Colony formation assays
comparing tolerance of parental and alpelisib-resistant cell lines to alpelisib treatment over time. Number of colonies was counted and graphed.
* represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, ns = not significant, unpaired Student’s t-test. e Immunoblot for PARP
cleavage in Cal33 and 93-VU-147T parental and alpelisib-resistant cells treated with alpelisib (5 μM) for 45 h, or staurosporine (2 μM) for 3 h, as a
positive control. Densitometric quantification of each protein relative to α-tubulin is shown below each band
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Statistical analysis
All analyses were performed with Prism® 7 GraphPad
Software. Experimental groups were compared with con-
trols using Student’s unpaired, two-tailed t-tests. Mul-
tiple groups were compared across a single condition
using one-way ANOVA. P < 0.05 was used to define sig-
nificant differences from the null hypothesis.
Results
Alpelisib inhibits growth and PI3K signalling in HNSCC
cells
Prior to exploring resistance to PI3K inhibition, we first
validated the efficacy of alpelisib in HNSCC cell lines.
Alpelisib treatment reduced signalling through both the
PI3K and MAPK pathways in Cal33 (PIK3CA mutant)
Fig. 3 Expression of AXL and TYRO3 is elevated in alpelisib-resistant cells. a Immunoblot with/without 5 μM alpelisib (36 h) in parental and resistant
Cal33 and 93-VU-147T cell lines using indicated antibodies. Densitometric quantification of each protein relative to α-tubulin is shown below each
band. b Heatmaps displaying RPPA results (top 50% of differentially-expressed proteins for each cell line is shown). Arrows indicate AXL and TYRO3. c
Immunoblot showing expression of TAM family RTKs AXL, TYRO3 and MER-TK in parental and alpelisib-resistant HNSCC cell lines. HEK293T cells are
included as a positive control for MER-TK expression. Densitometric quantification of each protein relative to α-tubulin is shown below each band
Ruicci et al. Journal of Experimental & Clinical Cancer Research          (2020) 39:217 Page 7 of 18
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cells and 93-VU-147T (PIK3CA amplified) cells (Fig. 1a),
as indicated by reduced levels of phosphorylated (p)-Akt
(Thr308), pERK1/2 (Thr202/Tyr204) and pP90RSK
(Ser380) [21]. Based on previous studies, we hypothe-
sized that the mechanism of action for alpelisib in
HNSCC would involve cell cycle arrest [7]. Following 24
h of treatment with alpelisib, we observed a significant
reduction in the proportion of proliferating (S-phase)
cells (Fig. 1b) [24, 25]. To determine whether alpelisib
was also able to induce cell death through apoptosis, we
examined PARP cleavage (Fig. 1c). Following alpelisib
treatment, cleaved PARP was readily detectable. Of note,
we have also previously characterized the sensitivity of
28 HNSCC cell lines to PI3K inhibition and found both
wildtype and PIK3CA-altered cell lines to be sensitive to
PI3K inhibition [21].
Genomically-distinct HNSCC cell lines develop resistance
to alpelisib
To identify pathways associated with acquired resistance
to alpelisib, we exposed two genomically-distinct HNSC
C cell lines (Fig. 2a) to increasing concentrations of alpe-
lisib over a 3–4 month period (schematic shown in Add-
itional Fig. 2), ultimately yielding cell lines significantly
more resistant to alpelisib than their parental counter-
parts (Fig. 2b-c) [21]. To verify the durability of the re-
sistant cell lines, parental and resistant cells were
challenged to grow as single cell colonies in the presence
of alpelisib. Whereas alpelisib treatment led to a signifi-
cant reduction in the number of colonies formed by
both parental cell lines, it was much less effective in re-
sistant cell lines (Fig. 2d). Although the alpelisib-
resistant 93-VU-147T cells exhibited a modest reduction
in colony formation following alpelisib treatment, the
difference was much less than that of the parental line.
Thus, cell lines treated for a prolonged period with alpe-
lisib exhibit increased tolerance for this PI3K inhibitor.
In addition, we examined the relative abundance of colony
sizes (small, medium, large) in parental versus resistant
cell lines as this reflects cell lines’ proliferative status
(Additional Fig. 3a-b). Finally, to compare the ability of
alpelisib to induce cell death through apoptosis, we exam-
ined PARP cleavage following alpelisib treatment in par-
ental and alpelisib-resistant cell lines (Fig. 2e). We found
that following alpelisib treatment, cleaved PARP was read-
ily detectable in parental cells, but was less abundant in
alpelisib-resistant cells, suggesting that alpelisib treatment
is less effective at inducing cell death via apoptosis in cells
that have acquired resistance to alpelisib.
To determine whether alpelisib continued to block sig-
nalling through the PI3K pathway in drug-resistant cells,
we used immunoblotting to examine Akt phosphorylation
following alpelisib treatment in parental and resistant cell
lines. In parental and drug-resistant cell lines alike, alpeli-
sib treatment suppressed Akt Thr308 and Ser473 phos-
phorylation, indicating that resistance was acquired via a
compensatory mechanism and not loss of direct inhibition
of PI3K activity (Fig. 3a).
Expression of AXL and TYRO3 is elevated in alpelisib-
resistant cells
To examine a broad array of signalling pathways that
could mediate resistance to PI3K inhibition in HNSCC
cells, we performed RPPAs on lysates from Cal33 and
93-VU-147T parental cells and resistant cell lines (Fig.
3b). In both resistant cell lines, RPPAs suggested that ex-
pression of the membrane-bound RTK AXL was ele-
vated relative to parental cells. As mentioned, AXL has
been previously shown to mediate resistance to various
anti-cancer agents, including EGFR, HER2 and PI3K-
targeted therapies [12, 26–28]. AXL is part of a three-
member RTK sub-family known as the ‘TAM family’ of
receptors (TYRO3, AXL, MER-TK) [29–32]. Interest-
ingly, expression of TYRO3 was also found to be ele-
vated in both Cal33 and 93-VU-147T alpelisib-resistant
cells. To our knowledge, TYRO3 has never been impli-
cated in PI3K-inhibitor resistance, nor in HNSCC as an
effector of therapy response. In general, much less is
known about TYRO3, including the role it plays in can-
cer development and progression [31–34].
We confirmed elevated protein expression of AXL and
TYRO3 in alpelisib-resistant Cal33 and 93-VU-147T cells,
relative to parental cells by immunoblotting (Fig. 3c). We
also examined expression of the third member of the
TAM RTK family, MER-TK, which was not included in
the RPPA. MER-TK was weakly detectable in both HNSC
C cell lines, in contrast to its high expression in HEK293T
cells (long exposure blots shown in Additional Fig. 4a-b).
As MER-TK was only weakly detected in both cell lines
and no difference in expression was apparent between
parental and drug-resistant cells, we did not examine it
further. Based on our findings, we hypothesized that over-
expression of TYRO3 and/or AXL receptors could play a
role in mediating resistance to PI3Kα inhibition.
(See figure on previous page.)
Fig. 4 Genomically-distinct HNSCC PDX models develop resistance to alpelisib following prolonged treatment. a Growth curves for PDX models
treated over time with alpelisib. 5 mice per arm received either alpelisib (50 mg/kg) or a vehicle agent (corn oil). * represents p < 0.05, **
represents p < 0.01, unpaired Student’s t-test. Boxed out region highlights early treatment days where alpelisib-treated tumors showed static
growth relative to the vehicle treatment. b Representative IHC sections showing TYRO3 staining in PDX-C and PDX-E models. Quantification was
completed using Fiji software and is shown below. * represents p < 0.05, unpaired Student’s t-test. Scale bars represent 100 μM
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Fig. 5 (See legend on next page.)
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HNSCC PDX models develop resistance to alpelisib
In parallel with our cell line models, we generated 5
PDX models from HNSCC patient tumors (clinical char-
acteristics outlined in Additional Table 4). Of the 5
models, one (PDX-B) was both HPV-positive and con-
tained a non-synonymous PIK3CA mutation (E545K)
[21]. The remaining models were all PIK3CA wildtype.
Several of the PDX models contained mutations fre-
quently seen in HNSCC, including TP53 mutations,
EGFR amplifications and CDKN2A alterations [4, 21].
Histological comparison of PDXs and their corresponding
primary tumors (where available) revealed a high degree of
similarity in their cellular morphology (Additional Fig. 5).
In all 5 PDX models, treatment with alpelisib significantly
suppressed tumor growth for the first 20–35 days, relative
to the vehicle agent (Fig. 4a, boxed regions). However, be-
yond this initial response period, alpelisib-treated tumors
began to resume growth or exhibit an increased rate of
growth over time (Fig. 4a). Thus, PDX models behave simi-
larly to cell lines in that they also spontaneously develop re-
sistance to PI3Kα inhibition by alpelisib over time.
Ki67 staining was used to examine the proliferative ac-
tivity of vehicle-treated tumors, alpelisib-sensitive tumors
(not treated to resistance) and alpelisib-resistant tumors.
Most vehicle-treated and alpelisib-resistant tumors exhib-
ited strong positive Ki67 staining, whereas alpelisib-
sensitive tumors showed weaker staining (representative
sections shown in Additional Fig. 6). We next analyzed
the expression of AXL and TYRO3 in PDX models using
IHC. While no difference in AXL expression was detected
for either model examined (Additional Fig. 7), TYRO3 ex-
pression following prolonged treatment with alpelisib was
elevated in both PDX models (Fig. 4b).
TYRO3 and AXL overexpression mediates resistance to
alpelisib
Since expression of AXL and TYRO3 were both elevated
in alpelisib-resistant models, we proceeded to determine
the relative expression of both receptors at the cell surface
in parental and resistant cells. Flow cytometric analysis
demonstrated a significant increase in both AXL and
TYRO3 surface levels in alpelisib-resistant Cal33 and 93-
VU-147T cells, compared to parental cells (Fig. 5a).
To assess whether the upregulation of TYRO3 and/or
AXL expression plays a causative role in mediating re-
sistance to PI3Kα inhibition, we used siRNAs to silence
each receptor in alpelisib-resistant cells. Knockdown of
either TYRO3 or AXL re-sensitized resistant cells to
alpelisib treatment, to a level almost comparable to their
parental (baseline) sensitivity (Fig. 5b). In 93-VU-147T
cells, combined TYRO3 and AXL knockdown sensitized
resistant cells to an even greater extent than their paren-
tal sensitivity, highlighting the role both receptors play
in modulating response to alpelisib treatment.
MAPK signalling is activated in alpelisib-resistant models
Since the expression of activated MAPK pathway mem-
bers ERK1/2 and P90RSK was reduced by PI3K inhibition
in parental cells (Fig. 1a) and the MAPK signalling path-
way is a downstream target associated with TAM RTKs,
we proceeded to examine the activation status of several
MAPK pathway members in our resistant cells (Fig. 6a)
[33]. Beginning upstream, we examined expression of the
scaffold protein GAB2 that mediates signalling from the
adaptor protein Grb2 on intracellular RTK domains to
RAS. GAB2 expression was elevated in alpelisib-resistant
93-VU-147T cells (as suggested in the RPPA), although
no difference was apparent in Cal33 cells (Fig. 6b, block
1). The next differentially-expressed pathway member was
phosphorylated MEK1 (Ser298) which was apparent in
alpelisib-resistant Cal33 cells (Fig. 6b, block 2). Moving
down the MAPK pathway, elevated activating phosphoryl-
ation of ERK1/2 and P90RSK was detected in all alpelisib-
resistant cell lines (Fig. 6b, block 3). Collectively, these ob-
servations reveal an induction of MAPK pathway activa-
tion upon prolonged treatment with alpelisib.
Given the upregulation of pP90RSK (Ser380) observed in
the resistant cell lines and its described involvement in
HNSCC oncogenesis, we proceeded to examine its expres-
sion in our PDX models using IHC [35, 36]. We observed a
non-significant trend towards elevated pP90RSK (Ser380) ex-
pression in alpelisib-resistant PDX-E tissues and a significant
increase in expression in PDX-C tissues (Fig. 6c-d).
Inhibition of MAPK signalling improves response to alpelisib
To evaluate the effect of MAPK signalling on resistant cells’
responsiveness to alpelisib, we targeted the downstream
MAPK pathway member P90RSK using the small molecule
inhibitor BI-D1870, alone and in combination with alpelisib
[37]. In both alpelisib-resistant cell lines, BI-D1870 treatment
resulted in a significant reduction in cell viability (Fig. 7a).
(See figure on previous page.)
Fig. 5 TYRO3 and AXL modulate sensitivity to alpelisib. a Flow cytometric analysis of AXL and TYRO3 in parental and resistant HNSCC cell lines.
Median fluorescence intensity (MFI) was measured and graphed for three biological replicates. * represents p < 0.05, ** represents p < 0.01, ***
represents p < 0.001, **** represents p < 0.0001, ns = not significant, unpaired Student’s t-test. b siRNA-mediated knockdown of AXL (siAXL) and
TYRO3 (siTYRO3) in Cal33 and 93-VU-147T cells. siCT = scrambled control siRNA, RNAi = RNA interference. ** represents p < 0.01, ns = not
significant. One-way ANOVA. Immunoblot of AXL and TYRO3 expression following siRNA-mediated knockdowns is shown below, siCT = scrambled
control siRNA. Densitometric quantification of each protein relative to α-tubulin is shown below each band
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When BI-D1870 and alpelisib treatments were combined,
greater decreases in cell viability were observed.
Knockdown of TYRO3 and AXL reduces MAPK pathway
activation
We next evaluated the relation between expression of
TYRO3 and AXL, and MAPK pathway activation. Fol-
lowing knockdown of TYRO3 and AXL in alpelisib-
resistant cells, we used immunoblotting to detect
phosphorylated (active form) members of the MAPK
pathway, including ERK1/2, P90RSK and S6 (Fig. 7b).
In Cal33 cells, silencing of either TYRO3 or AXL was
associated with reduced phosphorylation of P90RSK
(Ser380) and S6 (Ser235/6), while only TYRO3 silen-
cing reduced ERK1/2 (Thr202/Tyr204) phosphoryl-
ation. In 93-VU-147T cells, TYRO3 knockdown
reduced phosphorylation of ERK1/2 and P90RSK,
while AXL knockdown did not have an apparent ef-
fect on MAPK pathway activation.
Baseline expression of AXL and TYRO3 is not associated
with sensitivity to PI3K inhibition
To determine whether expression of TYRO3 and/or
AXL was associated with PI3K inhibitor sensitivity at
baseline (without prolonged drug exposure), we exam-
ined the protein expression of both receptors in a
panel of 25 HNSCC cell lines (Additional Table 1)
[20]. We previously characterized the sensitivity of all
25 lines to alpelisib and ordered the cell lines accord-
ingly [21]. While expression of both proteins varied
between cell lines, we did not observe a trend in the
expression of either TYRO3 or AXL that appeared to
correlate with sensitivity to alpelisib (Additional Fig.
8). Given an absence of a correlation between base-
line TAM RTK expression and response to PI3K in-
hibition, it appears the involvement of TYRO3 and
AXL in drug response is contingent on either the ac-
tivity of the receptors or a relative upregulation of re-
ceptors during the course of treatment that
subsequently affects drug response.
Activation of MAPK signalling and elevated TAM RTK
expression in a PDX-derived cell line
Finally, in parallel with our in vitro and in vivo models of
acquired resistance to PI3K inhibition, we treated our
PDX-derived cell line (PDX-C cell line) with alpelisib to
generate an alpelisib-resistant cell line. This model system
provided the unique opportunity to use an early-passage
tumor-derived cell line to validate the data from both our
in vitro studies using established HNSCC cell lines and
our in vivo studies using PDX models. The alpelisib-
resistant PDX-C-derived cell line had a ~ 3-fold increase
in IC50 (2.3 μM versus 6.3 μM), relative to its parental
counterpart (Fig. 7c). Immunoblotting revealed elevated
expression of AXL in the alpelisib-resistant cell line, while
TYRO3 expression appeared stable (Fig. 7d). We pro-
ceeded to evaluate the relative expression of AXL and
TYRO3 at the cell surface using flow cytometry. We ob-
served a significant increase in AXL surface levels in
alpelisib-resistant PDX-C cells, compared to in parental
cells (Fig. 7e). Downstream, elevated phosphorylation of
MAPK pathway members ERK1/2 and P90RSK was also
detected in alpelisib-resistant PDX-C cells, confirming our
previous in vitro and in vivo PDX findings (Fig. 7f).
Discussion
In this study, we demonstrate that PI3Kα inhibition ex-
hibits anti-tumor efficacy in HNSCC models by dampen-
ing PI3K signalling, inducing PARP cleavage and
reducing the proportion of actively-proliferating cells. As
targeted PI3Kα inhibition is under active clinical investi-
gation for HNSCC patients and has been FDA-approved
for breast cancer treatment already, we proceeded to
evaluate the efficacy of PI3Kα inhibition over time. We
show in both in vitro and in vivo assays that HNSCC es-
capes the anti-tumor activity of alpelisib over a period of
weeks to months. This acquisition of drug resistance is
associated with upregulation of the RTKs TYRO3 and
AXL, and an increase in signalling through the MAPK
network. While AXL has been described in various set-
tings to function as a mediator of acquired drug resist-
ance, the involvement of its family member TYRO3 is
previously unrecognized [12, 26, 27, 38, 39].
AXL and TYRO3 are two members of the three-
membered TAM family of RTKs, which also includes MER-
TK [32]. Although none of the TAM RTKs are considered
to be strong oncogenes, all three have demonstrated trans-
forming potential and it is increasingly recognized that their
overexpression contributes to resistance to both standard
and targeted chemotherapies [31, 40]. AXL is by far the best-
studied TAM RTK and has an established role in supporting
tumorigenesis through its positive effects on cellular survival,
migration, proliferation and invasion, and in mediating ac-
quired resistance [31]. To date, overexpression of AXL has
(See figure on previous page.)
Fig. 6 Activation of the MAPK signalling pathway in alpelisib-resistant cell lines and PDX models. a Schematic representation of PI3K and MAPK
pathways, with crosstalk activating mTORC1 shown. b Immunoblot with indicated parental and alpelisib-resistant lysates examining activation of
the MAPK pathway. Densitometric quantification of each protein relative to α-tubulin is shown below each band. c & d Representative IHC
sections showing pP90RSK (Ser380) staining in PDX-E c and PDX-C d models. Quantification was completed using Fiji software and is shown
below. *** represent p < 0.01, ns = not significant, unpaired Student’s t-test. Scale bars represent 50 μM
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been implicated in resistance to imatinib (BCR-Abl, c-Kit
and PDGFR inhibitor), lapatinib (HER2 inhibitor), erlotinib
(EGFR inhibitor) and cetuximab (EGFR-targeting monoclo-
nal antibody), as well as resistance to the chemotherapeutics
doxorubicin, cisplatin and etoposide (VP-16) in a variety of
solid tumor types and blood cancers [26, 27, 31, 38, 39, 41,
42]. In contrast, TYRO3 overexpression has been shown to
mediate taxol resistance in ovarian cancer and in general,
promote progression of various cancers when overexpressed
[31, 34, 43, 44].
In our HNSCC models, upregulation of both AXL and
TYRO3 total protein was detected, as was an increase in
cell surface localization in alpelisib-resistant versus par-
ental samples. The involvement of AXL and TYRO3 in
resistance to PI3Kα inhibition is underscored by the fact
that knockdown of either or both receptors significantly
sensitized cells to alpelisib treatment.
Across a large panel of HNSCC cell lines, we did not
observe a trend between protein expression of TYRO3
or AXL, and sensitivity to PI3Kα inhibition. This leads
us to believe that the involvement of AXL and TYRO3
in PI3K inhibitor resistance is likely based on a relative
increase in expression/surface localization or altered re-
ceptor activity, rather than a baseline expression level.
At present it is not well known how expression of AXL
and TYRO3 is regulated; given the emerging role of
TAM RTKs in cancer and drug response however, this
is an area of active research [32, 33]. Hypoxia and HIF-
1α expression has been associated with AXL expression
while certain microRNAs (miRNAs) are also thought to
be a mediator of TAM RTK expression [45–48].
Downstream of AXL and TYRO3, numerous intracel-
lular signalling pathways have been associated with can-
cer progression and drug resistance [32, 33]. Re-
activation of Akt signalling and activation of the NF-κB
pathway are two such examples [38, 39]. In the context
of HNSCC specifically, PLCγ-PKC signalling down-
stream of AXL has been identified following PI3Kα in-
hibition [12]. Our data provide evidence of MAPK
pathway activation, consistent across both cell lines sur-
veyed. Further, targeted inhibition of the downstream
MAPK pathway member P90RSK, alone and in combin-
ation with alpelisib, resulted in a significant reduction in
cell viability of alpelisib-resistant HNSCC cells,
emphasizing the relevance of this pathway in circum-
venting PI3K inhibition. Our observations are in accord-
ance with previous findings that have demonstrated RSK
family members to be mediators of resistance to PI3K
pathway inhibition in breast cancer, and to be capable of
promoting disease progression in HNSCC specifically
[35, 36].
Other studies have reported that residual mTORC1
activity following PI3K inhibition is involved with limit-
ing its anti-tumor efficacy [49, 50]. The activation of
MAPK signalling observed in our alpelisib-resistant
HNSCC cell lines supports this finding, as the MAPK
pathway intersects with the PI3K pathway at several
downstream points that promote mTORC1 or S6 activ-
ity (Fig. 7a) [51]. As well, Chandarlapaty et al. (2011) de-
scribed a direct association between inhibition of PI3K/
Akt signalling and upregulation of RTKs, such as HER3
and IGF-1R [52]. The pattern of receptor upregulation/
activation and intracellular signalling converging on
mTORC1/S6 may be a shared feature of acquired resist-
ance to PI3K pathway inhibition across different cancer
types [12, 52]. However, the particular mechanism and
mediator(s) adopted by tumor cells are likely cancer-
and/or drug-specific.
Recently, PDX models have emerged as a leading pre-
clinical platform through which to interrogate drug effi-
cacy, interpatient response heterogeneity and, more
recently, to elucidate mechanisms of drug resistance [18,
53, 54]. In our study, we confirmed in vitro findings of
TYRO3 and AXL upregulation and MAPK pathway acti-
vation upon prolonged PI3Kα inhibition in a panel of 5
unique HNSCC PDX models treated for up to 100 days
with alpelisib.
Based on our collective findings, pan-TAM inhibition
emerges as a logical combinatorial or second-line treat-
ment target alongside PI3Kα inhibition in HNSCC.
While AXL inhibitors are already in active development
owing to its identified role in drug resistance, our find-
ings reveal its family member TYRO3 to be similarly
relevant [31]. The importance of TYRO3 is particularly
evident through our in vivo models, where we found
TYRO3 protein expression to be significantly upregu-
lated in alpelisib-resistant PDX tissues, whereas the
changes in AXL expression were less apparent. We
(See figure on previous page.)
Fig. 7 Inhibition of MAPK signalling improves response to alpelisib. a Effect of P90RSK inhibitor BI-D1870 and alpelisib (5 μM each) on viability of
alpelisib-resistant cell lines. * represents p < 0.05, ** represents p < 0.01, **** represents p < 0.0001. One-way ANOVA. b Immunoblot of MAPK
pathway members following knockdown of AXL and TYRO3. siCT = scrambled control siRNA. Densitometric quantification of each protein relative
to α-tubulin is shown below each band. c Dose response curve comparing sensitivity of parental and alpelisib-resistant PDX-C cells to alpelisib. d
Immunoblot of parental and alpelisib-resistant PDX-C cell lysates for expression of TYRO3 and AXL RTKs. Densitometric quantification of each
protein relative to α-tubulin is shown below each band. e Flow cytometric analysis of AXL and TYRO3 in parental and resistant PDX-C cells.
Median fluorescence intensity (MFI) was measured and graphed for three biological replicates. * represents p < 0.05, ns = not significant, unpaired
Student’s t-test. f Immunoblot of parental and alpelisib-resistant PDX-C cell lysates for activation of the MAPK pathway. Densitometric
quantification of each protein relative to α-tubulin is shown below each band
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would therefore speculate that the use of a dual AXL/
TYRO3 or pan-TAM inhibitor (e.g. LDC1267) would be
more effective and durable over time [31]. To date, no-
specific TYRO3 inhibitors are available. Targeting the
MAPK pathway is an alternative approach, as we dem-
onstrated with the P90RSK inhibitor BI-D1870. How-
ever, MAPK pathway inhibition has had variable efficacy
to date and acquired resistance to inhibitors of the
MAPK pathway has been documented, in some cases in-
volving TAM RTKs [55, 56]. Upstream targeting of AXL
and TYRO3 therefore seems to be the most logical ap-
proach. Importantly, as AXL has been identified as a
drug resistance mediator to PI3K inhibition in several
cancer types, pan-TAM inhibition may be a sensible ap-
proach to preventing resistance in settings even beyond
HNSCC; this is a key area for future study.
Conclusion
In summary, our findings identify TYRO3/AXL upregu-
lation and MAPK pathway activation as a consequence
of prolonged PI3Kα inhibition, both in vitro and in vivo.
A therapeutic approach involving not only AXL inhib-
ition, but pan-TAM RTK inhibition may therefore help
to prevent, or at least delay, resistance to PI3K inhibitors
and improve outcomes for HNSCC patients.
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